PDS Biotech jumps on early data for experimental colon cancer drug

PDS Biotechnology

15/04/2026 13:58

** Shares of biotech firm PDS Biotechnology PDSB.O rise 3.8% to $1.10 premarket

** Co says in a mid-stage study, its experimental drug PDS01ADC showed strong response in metastatic colorectal cancer, a form of colon cancer that has spread and is hard to treat

** Trial run with the U.S. National Cancer Institute tested the drug in patients whose cancer had spread to the liver after other treatments failed, co says

** Says about 78% of patients responded to treatment and ~85% were alive after two years

** In a similar trial without the drug, response was ~35% and two-year survival ~40%, co says

** Says no major safety issues seen so far, but study involved only nine patients and was not randomized

** Adds that it plans larger trials to confirm results

** As of last close, stock up ~38% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))